Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J
Department of Rheumatology, Kivelä Hospital, Helsinki, Finland.
Br J Rheumatol. 1994 Nov;33(11):1012-6. doi: 10.1093/rheumatology/33.11.1012.
The new assay of cross-linked carboxyterminal telopeptide of type I collagen (ICTP), a serum marker for bone collagen degradation, was evaluated in serial measurements of 66 patients with early RA during a 3-yr prospective study. Initially 51% of RA patients had elevated levels of serum ICTP compared to healthy controls. During the subsequent months after starting anti-rheumatic treatment, the mean ICTP levels decreased in parallel with the clinical and laboratory variables measuring disease activity. Despite marked clinical improvement with anti-rheumatic treatment, a steady increase in radiological progression of joints was observed. Throughout the follow-up serum ICTP levels correlated with inflammatory parameters and from the first year on with the radiological changes assessed annually. However, initial serum ICTP levels correlated better than the other variables of disease activity with the subsequent erosive progression of joints indicating that measurement of serum ICTP may serve as one of the prognostic markers for joint damage in early RA.
在一项为期3年的前瞻性研究中，对66例早期类风湿关节炎（RA）患者进行了系列测量，评估了一种新的骨胶原降解血清标志物——I型胶原交联羧基末端肽（ICTP）检测方法。最初，与健康对照相比，51%的RA患者血清ICTP水平升高。在开始抗风湿治疗后的随后几个月里，ICTP平均水平随着测量疾病活动的临床和实验室指标而下降。尽管抗风湿治疗使临床症状明显改善，但仍观察到关节放射学进展持续增加。在整个随访过程中，血清ICTP水平与炎症参数相关，从第一年起与每年评估的放射学变化相关。然而，初始血清ICTP水平与疾病活动的其他变量相比，与随后关节的侵蚀性进展相关性更好，这表明血清ICTP检测可作为早期RA关节损伤的预后标志物之一。
